8,700 Shares of BioNTech SE Sponsored ADR $BNTX Bought by TB Alternative Assets Ltd.

TB Alternative Assets Ltd. purchased a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 8,700 shares of the company’s stock, valued at approximately $855,000. BioNTech accounts for about 0.2% of TB Alternative Assets Ltd.’s portfolio, making the stock its 26th biggest position.

Several other hedge funds have also recently bought and sold shares of the stock. Farther Finance Advisors LLC grew its position in shares of BioNTech by 31.5% in the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock valued at $48,000 after purchasing an additional 118 shares during the last quarter. AlphaCentric Advisors LLC increased its stake in shares of BioNTech by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company’s stock worth $499,000 after purchasing an additional 305 shares during the period. USS Investment Management Ltd increased its stake in shares of BioNTech by 1.2% during the first quarter. USS Investment Management Ltd now owns 32,577 shares of the company’s stock worth $2,854,000 after purchasing an additional 382 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in BioNTech during the 2nd quarter worth approximately $39,000. Finally, Marks Group Wealth Management Inc lifted its holdings in BioNTech by 16.0% during the 1st quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company’s stock worth $307,000 after purchasing an additional 476 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BioNTech

In other BioNTech news, CEO Ugur Sahin sold 72,000 shares of the business’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the completion of the transaction, the chief executive officer owned 108,209 shares of the company’s stock, valued at approximately $10,521,161.07. The trade was a 39.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 807,209 shares of company stock valued at $79,246,837 in the last quarter. Insiders own 19.20% of the company’s stock.

BioNTech Price Performance

BNTX stock opened at $90.20 on Friday. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The firm has a market cap of $22.81 billion, a P/E ratio of -11.52 and a beta of 1.25. The company’s 50-day moving average price is $99.10 and its two-hundred day moving average price is $95.33.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The business’s revenue was down 59.5% on a year-over-year basis. During the same period last year, the company posted ($1.60) EPS. On average, analysts anticipate that BioNTech SE Sponsored ADR will post -6.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

BNTX has been the subject of several recent research reports. Citigroup reduced their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, October 2nd. Canaccord Genuity Group cut their price objective on shares of BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $125.44.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.